An off-the-shelf, allogeneic NK-92–derived CAR-NK cell therapy engineered to express an anti-CD19 CAR for direct killing of CD19+ B cells, secrete ER-retained IL-2 to support NK activation/persistence, and express high-affinity CD16a (FcγRIIIa V158) to enhance ADCC.
Allogeneic NK-92–derived CAR-NK cells engineered with an anti-CD19 chimeric antigen receptor to recognize and kill CD19+ B cells via NK cytotoxic mechanisms (perforin/granzyme). The cells secrete ER-retained IL-2 to support NK activation and persistence and express high-affinity CD16a (Fc-gamma RIIIa V158) to enhance antibody-dependent cellular cytotoxicity, enabling synergy with therapeutic antibodies.
NO
INDIRECT
IgG1 Fc is on antibodies, not cell surfaces. CD19 t-haNK kills CD19+ cells via CAR and can mediate ADCC when cells are opsonized by IgG1 antibodies, but it does not target IgG1 Fc on cells.
CD19‑directed antibody‑drug conjugate that delivers a pyrrolobenzodiazepine (PBD) cytotoxic payload to B cells.
Humanized anti‑CD19 monoclonal antibody linked via a cleavable linker to a pyrrolobenzodiazepine (PBD) dimer. After binding CD19 on B cells and internalization, the linker is cleaved to release the PBD payload, which binds the DNA minor groove and forms interstrand cross‑links (N2 of guanine), blocking DNA replication and inducing cytotoxicity in CD19‑expressing tumor cells.
NO
INDIRECT
The ADC binds CD19 on B cells, is internalized, and releases a PBD payload that cross-links DNA at the N2 of guanine in the minor groove, blocking replication and killing CD19+ cells. DNA minor-groove binding is not the targeting determinant, so its presence alone does not confer cytotoxicity.
A chimeric IgG1 monoclonal antibody against CD20 that depletes B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric IgG1 monoclonal antibody targeting CD20 on B cells; depletes CD20-positive cells primarily via Fc-mediated antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Anti-CD20 antibody opsonizes B cells and triggers Fc-mediated ADCC by NK cells/macrophages, activates complement-dependent cytotoxicity, and can induce apoptosis of CD20+ cells.
Rabbit-derived polyclonal IgG targeting human T-cell antigens; depletes T cells (and some B/NK cells) via complement-dependent cytotoxicity, ADCC, and apoptosis.
Rabbit-derived polyclonal IgG that binds multiple human T‑cell antigens and depletes T cells (with some B/NK cell effects) via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis, producing profound lymphodepletion.
YES
DIRECT
rATG contains antibodies to CD2 that bind CD2+ cells and induce complement-dependent cytotoxicity and Fc-mediated ADCC, with additional apoptosis, depleting CD2-expressing cells.
Rabbit-derived polyclonal IgG targeting human T-cell antigens; depletes T cells (and some B/NK cells) via complement-dependent cytotoxicity, ADCC, and apoptosis.
Rabbit-derived polyclonal IgG that binds multiple human T‑cell antigens and depletes T cells (with some B/NK cell effects) via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis, producing profound lymphodepletion.
YES
DIRECT
Polyclonal antibodies in rATG bind CD3E on T cells and deplete them via complement-dependent cytotoxicity, Fc-mediated ADCC, and apoptosis.